MARKET CAP OF 3.3 MILLION WITH $9.6MILL IN CASH(Q3) AND $2.3MILL IN Q4 REVENUES!! (UNAUDITED)
LAST 2 PERIODS SHOW A MASSIVE 123%(UNAUDITED) AND 120% QUARTER OVER QUARTER GROWTH
TOTAL REVENUES OF $4.1M (UNAUDITED) IN FISCAL YEAR 2023, REPRESENTING A 276% INCREASE OVER THE PREVIOUS FISCAL YEAR
FOR THE NINE MONTHS ENDING MARCH 31, 2023, THEIR SUBSIDIARY DELIVERED $1.8 MILLION IN RARE CANNA - BINOID INGREDIENT SALES TO DISTRIBUTORS AND MANUFACTURERS IN THE H&W SECTOR, COMPARED TO $0.6 MILLION IN 2022
Hello Everyone,
We have another exciting profile to look at for tomorrow's session.
Our last profile from Wednesday saw an average trade of 2.03 on the session and today it hit highs of 2.53!! This was a 24% move in just two sessions.
Up next is an extremely unique hybrid company. They have several pharmaceutical programs supported by a revenue generating business.
If this kind of growth continues then they have the possibility of being a self funded pharma company.
The last time we profiled this one back in March it saw an average trade of 1.18 on the session. Less than 2 weeks later it hit 1.89 for a potential gain of 60% on exciting interest.
They are a global leader in the research, development and manufacturing of rare canna - binoids, including clinical and preclinical programs targeting the treatment of diseases with high unmet medical needs. They also have significant know-how in developing proprietary manufacturing approaches to produce canna - binoids for various market sectors.
Things appear to be heading in the right direction for this one if you look at the numbers. The company has had to optimize and scale up the manufacturing processes over the last 12 months to meet increasing demand. The company's BayMedica subsidiary delivered $1.8 million in rare canna - binoid ingredient sales to distributors and manufacturers in the H&W sector in the first 9 months of the fiscal year, compared to $0.6 million in all of 2022.
Another major catalyst is the valuation gap. If you look at the current market cap it is a mere fraction of the cash position. We often see companies valued at multiples of current revenues.
The market cap is 3.3 Mill with Q4 (Unaudited) revenues of 2.3 Mill and growing.
These two factors could be major factors towards the growth of this company from it's current levels.
Please Read the Full Profile Here: https://insiderfinancial.com/newalert
Sincerely,
DISCLAIMER
THIS WEBSITE/NEWSLETTER IS A PUBLICATION OF ONE22 MEDIA, LLC, HEREIN REFERRED TO AS O22. O22’S REPORTS/RELEASES ARE A COMMERCIAL ADVERTISEMENT AND ARE FOR GENERAL INFORMATIONAL PURPOSES ONLY.O22 IS ENGAGED IN THE BUSINESS OF MARKETING AND ADVERTISING COMPANIES FOR MONETARY COMPENSATION.
WE EXPECT TO BE COMPENSATED TWELVE THOUSAND FIVE HUNDRED DOLLARS DIRECTLY BY THE ISSUER. WE HAVE PREVIOUSLY BEEN COMPENSATED A FEE OF TWENTY FIVE THOUSAND USD FOR 1 ONE DAY AWARENESS CAMPAIGNS BY A THIRD PARTY, NORTH EQUITIES CORP BACK ON NOVEMBER 08 2022. WE HAVE BEEN COMPENSATED AN ADDITIONAL FIVE THOUSAND DOLLARS DIRECTLY BY THE ISSUER.
BY SUBSCRIBING TO OR OTHERWISE USING THIS WEBSITE/NEWSLETTER, YOU AGREE TO HOLD O22 AND ITS OPERATORS, OWNERS, AND EMPLOYEES HARMLESS AND TO COMPLETELY RELEASE THEM FROM ANY AND ALL LIABILITY DUE TO ANY AND ALL LOSS, DAMAGE, OR INJURY THAT YOU MAY INCUR, MONETARY OR OTHERWISE.
INVESTING IN MICRO-CAP AND GROWTH SECURITIES IS HIGHLY SPECULATIVE AND CARRIES AN EXTREMELY HIGH DEGREE OF RISK. NEVER INVEST IN ANY STOCK FEATURED ON O22’S SITE OR NEWSLETTER UNLESS YOU CAN AFFORD TO LOSE YOUR ENTIRE INVESTMENT. THE DISCLAIMER IS TO BE READ AND FULLY UNDERSTOOD BEFORE USING O22’S SERVICES, JOINING O22’S SITE OR EMAIL/BLOG LIST, OR FOLLOWING ANY SOCIAL NETWORKING PLATFORMS O22 MAY USE.
PLEASE NOTE WELL: O22 IS NOT A REGISTERED INVESTMENT ADVISOR, BROKER DEALER OR A MEMBER OF ANY ASSOCIATION FOR OTHER RESEARCH PROVIDERS IN ANY JURISDICTION WHATSOEVER. O22 IS NOT AFFILIATED WITH ANY EXCHANGE, ELECTRONIC QUOTATION SYSTEM, THE SECURITIES AND EXCHANGE COMMISSION, OR FINRA. NONE OF THE MATERIALS OR ADVERTISEMENTS HEREIN CONSTITUTE OFFERS OR SOLICITATIONS TO PURCHASE OR SELL SECURITIES OF THE COMPANIES PROFILED.
THE INFORMATION CONTAINED HEREIN IS BASED ON INFORMATION SUPPLIED BY THE COMPANIES PROFILED, PUBLICLY AVAILABLE INFORMATION, PRESS RELEASES, AND OTHER SOURCES WHICH O22 BELIEVES TO BE RELIABLE, BUT IS NOT GUARANTEED BY O22 AS BEING ACCURATE AND DOES NOT PURPORT TO BE A COMPLETE STATEMENT OR SUMMARY OF THE AVAILABLE DATA. O22 IS NOT RESPONSIBLE FOR ANY CLAIMS MADE BY THE COMPANIES PROFILED. INVESTORS SHOULD NOT RELY ON THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER IN DECIDING TO INVEST OR MAKE OTHER FINANCIAL DECISIONS. RATHER, INVESTORS SHOULD USE THE INFORMATION CONTAINED IN THIS WEBSITE/NEWSLETTER AS A STARTING POINT FOR DOING ADDITIONAL INDEPENDENT RESEARCH ON THE FEATURED COMPANIES. O22 STRONGLY ENCOURAGES READERS AND INVESTORS TO CONDUCT A COMPLETE AND INDEPENDENT INVESTIGATION OF THE RESPECTIVE COMPANIES, INCLUDING BY REVIEWING SEC FILINGS (FORMS 10-Q, 10-K, 8-K, 3, 4, 5, SCHEDULE 13D) AND BY CONSULTING YOUR OWN TAX, BUSINESS, FINANCIAL, AND INVESTMENT ADVISORS.
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 PROVIDES A SAFE HARBOR IN REGARD TO FORWARD-LOOKING STATEMENTS. ANY STATEMENTS THAT EXPRESS OR INVOLVE DISCUSSIONS WITH RESPECT TO PREDICTIONS, EXPECTATIONS, BELIEFS, PLANS, PROJECTIONS, OBJECTIVES, GOALS, ASSUMPTIONS OR FUTURE EVENTS OR PERFORMANCE ARE NOT STATEMENTS OF HISTORICAL FACT, AND MAY BE FORWARD-LOOKING STATEMENTS. FORWARD-LOOKING STATEMENTS ARE BASED ON EXPECTATIONS, ESTIMATES, AND PROJECTIONS AT THE TIME THE STATEMENTS ARE MADE THAT INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES WHICH COULD CAUSE ACTUAL RESULTS OR EVENTS TO DIFFER MATERIALLY FROM THOSE PRESENTLY ANTICIPATED. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED THROUGH USE OF WORDS SUCH AS PROJECTS, FORESEES, EXPECTS, ANTICIPATES, ESTIMATES, BELIEVES, UNDERSTANDS, MAY, COULD, OR MIGHT. THERE IS NO GUARANTEE THAT PAST PERFORMANCE WILL BE INDICATIVE OF FUTURE RESULTS.
Insider Financial
1337 Mass. AveBox 211
Arlington, MA 02476
No comments:
Post a Comment